Emma Walmsley

This page shows the latest Emma Walmsley news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Trump arrives in London, NICE says no to Darzalex, Pfizer backs down on prices

s Emma Walmsley.

Daily Brief: Crunch time for Brexit, GSK CEO RSVP from Trump

GlaxoSmithKline’s Emma Walmsley and J&J’s Alex Gorsky are among 150 business leaders who have been invited to dine with Donald Trump when he visits the UK next week.
GSK’s vaccines president Debruyne heads for the exit

Since Emma Walmsley took the helm of GlaxoSmithKline (GSK), the UK’s largest drug maker has been at the mercy of some rigorous, but some analysts would say necessary, staff changes.
Merck’s Brexit contingency plan? Stockpile medicines

GlaxoSmithKline chief executive Emma Walmsley said earlier this year that a transition deal needed to be agreed by April in order to give business two years to prepare for the impact
GSK gets maintenance indication for Trelegy

GSK’s total revenues were down 2% to £7.2bn. On a conference call, GSK chief executive Emma Walmsley said the company had made good progress in the quarter with sales
Morning brief: Takeda closes in on $64bn merger, GSK unveils team, and more

The firm is undergoing a rapid reinvigoration as chief executive Emma Walmsley assembles a new top executive team across all functions. ... Expected to be present on the call this afternoon is Hal Barron, the firm’s new Chief Scientific Officer and

More from news
Approximately 2 fully matching, plus 24 partially matching documents found.

Diversity and inclusion in the pharma industry

If, as GlaxoSmithKline CEO Emma Walmsley said, talking about diversity to Business Insider UK, ‘‘You cannot be a modern employer in an industry that should be future facing and modernising arguably
30 women leaders in UK healthcare (part 3)

29. Emma Walmsley, GSK CEO. Emma Walmsley is the first-ever leader of a big pharma company, having taken on the CEO role at GlaxoSmithKline in April 2017. ... Since then, Walmsley has very definitely put her own stamp on the firm, making major changes in
Pharma deals continue to slide

Emma Walmsley, CEO of GSK, said: “We will use cash for business development purposes, with M&A obviously dependent on the right kind of return profile.”.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

GSK appoints president of global pharmaceuticals

Emma Walmsley, GSK's chief executive officer designate, said: “ Luke brings a combination of excellent R&D insight and a strong track record of commercial execution. “

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Home based, Principal Medical Writer, Medical Communications: Excellent package

Account Director, Consumer Healthcare PR, Global PR agency: £50, 000 – £58, 000

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Home based, Senior Medical Writer, Medical Communications: Excellent package

Home based, Editorial Team Leader, Medical Communications: Excellent package

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Add my company

Specialising in medical device market research, our approach is people-centric and we thrive on making connections with clients and research...

Developing advocacy in the pharmaceutical industry.: The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?: Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?: The modern approach to B2B sales is data-driven, and enabled by digital tools....